Ardelyx Soars 11.39% on Strong Q2 Earnings, IBSRELA Sales

Ardelyx's stock surged by 11.39% in pre-market trading on August 5, 2025, driven by a series of positive developments and financial results.

Ardelyx reported a strong second quarter of 2025, with total revenue reaching nearly $100 million, marking a 33% increase compared to the same period in 2024. This growth was primarily driven by the sales of IBSRELA and XPHOZAH, with IBSRELA generating $65.0 million in net sales, an 84% year-over-year increase. However, XPHOZAH's revenue saw a decline due to the loss of Medicare coverage, highlighting the challenges in navigating regulatory environments.

The company also announced that its Chief Financial Officer, Justin Renz, will transition out by the end of 2025. Despite this change, Ardelyx's financial performance remains robust, with a strong cash position of $238.5 million in cash, cash equivalents, and investments. The company has raised its 2025 IBSRELA sales forecast to $250-$260 million, reflecting its strategic execution and market penetration.

Ardelyx's net loss for the quarter was $19.1 million, or $(0.08) per share, which is an improvement compared to the estimated EPS of -0.12. The company's research and development expenses increased to $15.7 million, and selling, general, and administrative expenses rose to $84.0 million, supporting the commercialization efforts of its key products.